AU2021276301A1 - Fused ring compounds, preparation method therefor, pharmaceutical compositions and use thereof - Google Patents

Fused ring compounds, preparation method therefor, pharmaceutical compositions and use thereof Download PDF

Info

Publication number
AU2021276301A1
AU2021276301A1 AU2021276301A AU2021276301A AU2021276301A1 AU 2021276301 A1 AU2021276301 A1 AU 2021276301A1 AU 2021276301 A AU2021276301 A AU 2021276301A AU 2021276301 A AU2021276301 A AU 2021276301A AU 2021276301 A1 AU2021276301 A1 AU 2021276301A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
halogenated
prodrug
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021276301A
Other languages
English (en)
Inventor
Daiguo DENG
Zengrong LEI
Guanpeng QIU
Yonggang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Fermion Technology Co Ltd
Original Assignee
Guangzhou Fermion Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Fermion Technology Co Ltd filed Critical Guangzhou Fermion Technology Co Ltd
Publication of AU2021276301A1 publication Critical patent/AU2021276301A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021276301A 2020-05-21 2021-05-21 Fused ring compounds, preparation method therefor, pharmaceutical compositions and use thereof Pending AU2021276301A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010433988 2020-05-21
CN202010433988.6 2020-05-21
CN202110529033 2021-05-14
CN202110529033.5 2021-05-14
PCT/CN2021/095191 WO2021233427A1 (zh) 2020-05-21 2021-05-21 并环化合物及其制备方法、药物组合物和应用

Publications (1)

Publication Number Publication Date
AU2021276301A1 true AU2021276301A1 (en) 2023-01-19

Family

ID=78672734

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021276301A Pending AU2021276301A1 (en) 2020-05-21 2021-05-21 Fused ring compounds, preparation method therefor, pharmaceutical compositions and use thereof

Country Status (8)

Country Link
US (1) US20230192683A1 (https=)
EP (1) EP4155305A4 (https=)
JP (1) JP7774312B2 (https=)
KR (1) KR20230015333A (https=)
CN (2) CN115991703A (https=)
AU (1) AU2021276301A1 (https=)
TW (1) TWI910166B (https=)
WO (1) WO2021233427A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI860849B (zh) 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽
KR20240122964A (ko) 2023-02-06 2024-08-13 에이치엘만도 주식회사 피스톤 밸브 조립체 및 이를 구비한 쇼크 업소버
JP2026509366A (ja) 2023-03-10 2026-03-18 イーライ リリー アンド カンパニー Ｓｓｔｒ４アゴニスト及びその塩の調製のための方法
AU2024236692A1 (en) 2023-03-10 2025-10-16 Eli Lilly And Company Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof
WO2024245077A1 (zh) * 2023-05-29 2024-12-05 武汉熙瑞医药科技有限公司 3-氮杂-双环[3.1.0]己烷衍生物、其制备方法及其应用
WO2025096300A1 (en) 2023-10-30 2025-05-08 Eli Lilly And Company Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives
CN120965687A (zh) * 2024-05-17 2025-11-18 广州费米子科技有限责任公司 Sstr4激动剂类化合物的晶体形式及其制备方法和用途
WO2025247982A1 (en) 2024-05-29 2025-12-04 Grünenthal GmbH Piperazines which act as sstr4 modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2685828A4 (en) * 2011-03-17 2014-08-13 Merck Sharp & Dohme SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS
KR101556318B1 (ko) * 2013-05-15 2015-10-01 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체
US9371282B2 (en) * 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
EP3045448A4 (en) 2013-09-12 2017-01-25 Sumitomo Chemical Company Limited Nitrogen-containing saturated heterocyclic compound
CN105315293A (zh) * 2014-07-29 2016-02-10 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途

Also Published As

Publication number Publication date
CN115991703A (zh) 2023-04-21
WO2021233427A1 (zh) 2021-11-25
JP7774312B2 (ja) 2025-11-21
US20230192683A1 (en) 2023-06-22
EP4155305A4 (en) 2024-07-10
TW202146402A (zh) 2021-12-16
TWI910166B (zh) 2026-01-01
EP4155305A1 (en) 2023-03-29
JP2023526791A (ja) 2023-06-23
CN113717167B (zh) 2022-12-02
CN113717167A (zh) 2021-11-30
KR20230015333A (ko) 2023-01-31

Similar Documents

Publication Publication Date Title
AU2021276301A1 (en) Fused ring compounds, preparation method therefor, pharmaceutical compositions and use thereof
CN113929693B (zh) 含氮杂环化合物、药物组合物和应用
KR20220130168A (ko) 피리미딘-4(3h)-케톤 헤테로시클릭 화합물, 그의 제조 방법, 및 의약 및 약리학에서의 그의 용도
CN113717161B (zh) 含氮饱和杂环化合物及其制备方法、药物组合物和应用
JP2003513069A (ja) １，４置換ピペリジニルｎｍｄａｎｒ２ｂアンタゴニスト
CN115028648B (zh) 三并环化合物及其药物组合物和应用
EP3760628A1 (en) Peptidylarginine deiminase inhibitor and use thereof
EP3375781A1 (en) Benzo ring derivative with b2 receptor agonist and m3 receptor antagonist activities and use thereof in medicine
CN117122598A (zh) 吗啡喃衍生物的在阿片δ受体激动剂相关疾病的治疗中的应用
EP3418277B1 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
KR20250162889A (ko) 트리아진계 화합물 및 이의 용도
ES2660876T3 (es) Derivados de piridona como inhibidores de la secreción de ácido y proceso para la preparación de los mismos
CN112778274B (zh) 一种含氮杂环衍生物及其制备
TWI916367B (zh) 含氮飽和雜環化合物及其製備方法、藥物組合物和應用
HK40062713B (en) Fused-ring compounds, preparation method, pharmaceutical composition and use thereof
HK40062713A (en) Fused-ring compounds, preparation method, pharmaceutical composition and use thereof
US8742120B2 (en) Methods of preparing factor xa inhibitors and salts thereof
CN121895338A (zh) 一种稠合环类化合物、包含其的药物组合物及其用途
KR101508214B1 (ko) 신규한 아졸-접합 피리딜 우레아 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
US20220259213A1 (en) Pyrrolopyrazole derivatives, preparation method thereof and application thereof in medicine
NO et al. 3rd Phase, Bangalore 560078 (IN).
NZ755300B2 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
NZ755300A (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
CA3008653A1 (en) Bruton's tyrosine kinase inhibitors